Expert Interview
A Second View - Prescriber Check In: The use of Provention Bio's Templizumab (Tzield) in delaying the onset of stage 3 type 1 diabetes in patients with stage 2 type 1 diabetes.
Ticker(s): PRVB, VRTXInstitution: UT Southwestern Medical Center
- Board-certified endocrinologist, Professor of medicine, and Director of the Diabetes Clinic at UT Southwestern Medical Center and Parkland Hospital.
- Currently manages 200 patients with Type 1 Diabetes and 10 patients that use the Omnipod System.
- Clinical research interests include diabetes management, prevention, and novel treatments while serving as the chair of Biomedical research.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
